MetaCap

Aktis Oncology (AKTS) vs Omeros (OMER)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Omeros is the larger company by market cap ($983.7 million vs $901.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AKTS-27.90%OMER+5.76%
+74%+17%-40%
Jan 9, 20261 yearNov 20, 2026
AKTS-27.90%OMER+5.76%
+65%+14%-37%
Jan 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AKTS versus OMER key metrics
MetricAKTSOMER
Share price$16.15$13.21
Market cap$901.14M$983.66M
1-day change-1.52%-5.71%
YTD return—-23.11%
1-year return—+48.93%
5-year return—+77.79%
P/E ratio (TTM)—15.92
Forward P/E—11.95
EPS (TTM)$-1.80$0.83
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-3.35M
52-week high$34.19$21.24
52-week low$13.96$6.70
Distance from 52-week high-52.76%-37.81%
Analyst consensusstrong_buybuy
Avg. price target upside+122.17%+108.18%
Average volume408.46K1.36M
Shares outstanding53.93M74.46M
Employees79175
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Aktis Oncology

AKTS stock →

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees

About Omeros

OMER stock →

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 175 employees

AKTS vs OMER FAQ

Which is bigger, Aktis Oncology or Omeros?

Omeros (OMER) is larger, with a market capitalization of $983.66M compared with $901.14M for Aktis Oncology (AKTS).

Are Aktis Oncology and Omeros in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons